The global Insomnia Therapeutic Market witnessed substantial growth in 2022, with a market size of USD 3,745 million. Projections indicate that this market will continue to expand, reaching a substantial value of USD 6,885.03 million by 2032, exhibiting a robust compound annual growth rate (CAGR) of 7% during the forecast period. Several factors contribute to this remarkable growth, including the increasing prevalence of insomnia worldwide, driven by shifts in lifestyle and elevated stress levels. Insomnia, a sleep disorder characterized by difficulties in falling asleep, staying asleep, or waking up prematurely, can have profound implications for an individual's physical and mental health, potentially leading to chronic conditions such as depression, anxiety, and hypertension.
To address the growing need for effective and secure insomnia treatments, there has been a surge in new drug formulations and advancements in sleep medicine technology. Additionally, the availability of diverse pharmaceutical and non-pharmacological treatment options is expected to further bolster market revenue. Non-pharmacological treatments like Cognitive-Behavioral Therapy (CBT) and relaxation techniques are gaining popularity due to their efficacy and safety profile.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/7356
The demand for insomnia therapies is poised to rise further due to an aging population and an increased prevalence of comorbidities such as diabetes and cardiovascular disorders. The utilization of Telemedicine and Digital health technology is expected to facilitate Remote Patient Monitoring, personalized care, and improved treatment outcomes. Furthermore, wearable technology and smartphone apps designed to track sleep patterns and provide feedback to both patients and healthcare professionals are driving market revenue growth.
Government Regulations: Various government bodies play a crucial role in regulating the insomnia therapeutic market:
- The United States Food and Drug Administration (FDA) mandates that manufacturers of Over-The-Counter (OTC) sleep aids and drugs used for insomnia submit safety data through Investigational New Drug Applications before marketing their products.
- The FDA publishes a list of approved OTC sleep aids and drugs for treating insomnia that must meet specific requirements before they can be sold in the market.
- The Centers for Medicare Medicaid Services (CMS) administers policies governing reimbursement for prescription medications used to treat insomnia.
- The Occupational Safety and Health Administration (OSHA) has issued guidelines for employers on providing shift workers with insomnia therapeutics such as melatonin or other sleep aids.
- The National Institute for Standards and Technology (NIST) develops standards for testing the effectiveness of insomnia therapeutics and other drugs used to treat sleep disorders, ensuring that these standards reflect the latest advancements in technology and research.
Key Takeaways:
Treatment Type Outlook:
The global insomnia therapeutic market can be categorized into four treatment types: prescription drugs, over-the-counter drugs, medical devices, and others. In 2022, prescription pharmaceuticals held the largest market share.
Prescription medications like benzodiazepines, nonbenzodiazepines, and orexin receptor antagonists are commonly used to treat insomnia, aiding patients in falling asleep more easily and staying asleep longer. Their widespread availability and effectiveness have contributed to their dominance in the market, especially as the global prevalence of insomnia continues to rise.
Over-the-counter drugs are expected to experience significant revenue growth during the forecast period. These include readily available options like antihistamines, melatonin, and valerian root, which do not require a prescription. The growing demand for over-the-counter medicines, driven by an aging population and increased awareness of sleep disorders, is fueling this segment's revenue expansion.
The category of medical devices, including continuous positive airway pressure (CPAP) machines and devices for sleep apnea treatment, is also projected to witness substantial revenue growth. The rising prevalence of sleep apnea and related disorders has led to increased demand for these portable and user-friendly devices.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/7356
Application Outlook:
The global therapeutic insomnia market is divided into three application-based segments: transient insomnia, short-term insomnia, and chronic insomnia. In 2022, chronic insomnia accounted for the highest revenue share.
Chronic insomnia, a severe and persistent form of the condition lasting more than three months, significantly impacts an individual's daily life and can lead to various health issues. Prescription medications like benzodiazepines and non-benzodiazepines are commonly used to treat chronic insomnia due to their effectiveness.
Short-term insomnia, which lasts from a few days to a few weeks and is often triggered by stress or anxiety, is expected to experience significant revenue growth during the forecast period. The growing aging population and increased awareness of sleep disorders are driving the demand for short-term insomnia therapies.
Regional Outlook:
In 2022, the North American market dominated the global insomnia therapeutic market in terms of revenue. This dominance is attributed to the high prevalence of insomnia in the region, primarily due to lifestyle changes, stress, and increased work demands. The United States, with nearly 70 million people suffering from sleep disorders, including insomnia, leads the market in the region.
The Asia Pacific market is expected to experience the fastest revenue CAGR during the forecast period, driven by rising awareness of insomnia and related treatments, increasing disposable income, and a more developed healthcare system. Key contributors to market growth in the Asia Pacific include China, Japan, and India, with China's aging population and rising insomnia prevalence driving demand for insomnia medicines.
The European market is projected to expand moderately during the forecast period, with increasing insomnia prevalence due to changing lifestyles, work pressure, and elevated stress levels. The United Kingdom stands out as the largest market in the region for insomnia treatments.
Competitive Landscape:
The global insomnia therapeutic market is characterized by a high degree of fragmentation, with several large and medium-sized players contributing to a significant share of market revenue. Major players are adopting various strategies, including mergers and acquisitions, strategic agreements, and the development and introduction of more effective products. Some of the prominent companies in the market include:
- Sanofi S.A.
- Merck Co., Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Eisai Co., Ltd.
- Purdue Pharma L.P.
- GlaxoSmithKline plc
- Johnson Johnson Services, Inc.
- Astellas Pharma Inc.
- Sunovion Pharmaceuticals Inc.
In conclusion, the global insomnia therapeutic market is witnessing substantial growth due to the increasing prevalence of insomnia, advancements in treatment options, and rising awareness of the importance of addressing sleep disorders. While challenges like generic medications and cost-containment strategies exist, the market is poised for significant expansion, especially in regions with growing aging populations and changing lifestyles.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/7356
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Chronic Inflammatory Demyelinating Polyneuropathy Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
